Willeke Ros

3.2k total citations · 3 hit papers
22 papers, 2.2k citations indexed

About

Willeke Ros is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Willeke Ros has authored 22 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Immunology. Recurrent topics in Willeke Ros's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Willeke Ros is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Willeke Ros collaborates with scholars based in Netherlands, United States and France. Willeke Ros's co-authors include Jan H.M. Schellens, Jos H. Beijnen, Sarina A. Piha‐Paul, Hyun Cheol Chung, Antoîne Italiano, Jean‐Pierre Delord, Scott K. Pruitt, Neeltje Steeghs, Marleen Kok and Kimberley M. Heinhuis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Willeke Ros

21 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

2019 714 citations Hyun Cheol Chung, Willeke Ros et al. Journal of Clinical Oncology profile →
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

2019 404 citations Kimberley M. Heinhuis, Willeke Ros et al. Annals of Oncology profile →
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

2020 335 citations Sarina A. Piha‐Paul, Do‐Youn Oh et al. International Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Willeke Ros Netherlands	14	1.6k	666	593	436	303	22	2.2k
Michael Teneriello United States	17	1.1k 0.7×	535 0.8×	212 0.4×	308 0.7×	121 0.4×	33	2.3k
Saeed Rafii United Kingdom	13	1.0k 0.6×	395 0.6×	242 0.4×	231 0.5×	103 0.3×	34	1.5k
Shoji Kodama Japan	20	806 0.5×	473 0.7×	395 0.7×	227 0.5×	268 0.9×	40	2.6k
Sharon X. Liang United States	24	1.1k 0.7×	655 1.0×	278 0.5×	547 1.3×	173 0.6×	57	3.2k
Natalja T. ter Haar Netherlands	26	677 0.4×	270 0.4×	384 0.6×	184 0.4×	332 1.1×	51	2.1k
Dominique Berton-Rigaud France	18	1.0k 0.6×	246 0.4×	440 0.7×	238 0.5×	49 0.2×	73	1.8k
Sherri Z. Millis United States	25	1.1k 0.7×	435 0.7×	180 0.3×	852 2.0×	141 0.5×	93	2.3k
George J. Olt United States	16	767 0.5×	680 1.0×	219 0.4×	297 0.7×	363 1.2×	38	2.3k
Gina Mantia-Smaldone United States	19	751 0.5×	271 0.4×	492 0.8×	140 0.3×	57 0.2×	56	1.8k
Leigh Marcus United States	12	1.1k 0.7×	311 0.5×	217 0.4×	488 1.1×	108 0.4×	18	1.6k

Countries citing papers authored by Willeke Ros

Since Specialization

Citations

This map shows the geographic impact of Willeke Ros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willeke Ros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willeke Ros more than expected).

Fields of papers citing papers by Willeke Ros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willeke Ros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willeke Ros. The network helps show where Willeke Ros may publish in the future.

Co-authorship network of co-authors of Willeke Ros

This figure shows the co-authorship network connecting the top 25 collaborators of Willeke Ros. A scholar is included among the top collaborators of Willeke Ros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willeke Ros. Willeke Ros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations

Piha‐Paul, Sarina A., Do‐Youn Oh, Makoto Ueno, et al.. (2020). Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies. International Journal of Cancer. 147(8). 2190–2198. 335 indexed citations breakdown →

Chiappori, Alberto, John A. Thompson, Fredericus Eskens, et al.. (2020). P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort. Poster presentations. A9–A10. 11 indexed citations

Chung, Hyun Cheol, Willeke Ros, Jean‐Pierre Delord, et al.. (2019). Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology. 37(17). 1470–1478. 714 indexed citations breakdown →

Heinhuis, Kimberley M., Willeke Ros, Marleen Kok, et al.. (2019). Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology. 30(2). 219–235. 404 indexed citations breakdown →

Pluim, Dick, et al.. (2019). Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab. Cytometry Part A. 95(10). 1053–1065. 13 indexed citations

Pluim, Dick, Willeke Ros, Mark T. J. van Bussel, et al.. (2018). Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. Journal of Pharmaceutical and Biomedical Analysis. 164. 128–134. 60 indexed citations

Melero, Ignacio, Morten Mau‐Sørensen, Ulrik Lassen, et al.. (2018). Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). Annals of Oncology. 29. viii134–viii135. 18 indexed citations

Chung, Hyun Cheol, José A. López-Martín, Wilson H. Miller, et al.. (2018). Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.. Journal of Clinical Oncology. 36(15_suppl). 8506–8506. 130 indexed citations

10.

Mau‐Sørensen, Morten, Willeke Ros, María E. Rodríguez-Ruiz, et al.. (2018). Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).. Journal of Clinical Oncology. 36(15_suppl). e15155–e15155. 36 indexed citations

11.

Hamid, Omid, Siwen Hu‐Lieskovan, Willeke Ros, et al.. (2018). Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs). Annals of Oncology. 29. viii422–viii422. 2 indexed citations

12.

Hamid, Omid, Willeke Ros, John A. Thompson, et al.. (2017). Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb. Annals of Oncology. 28. v406–v406. 2 indexed citations

13.

Segal, Neil H., Ignacio Melero, Willeke Ros, et al.. (2017). Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v134–v134. 23 indexed citations

14.

Melero, Ignacio, Neil H. Segal, Willeke Ros, et al.. (2017). Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors. Annals of Oncology. 28. v28–v28. 2 indexed citations

15.

El-Khoueiry, Anthony B., Omid Hamid, John A. Thompson, et al.. (2017). The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).. Journal of Clinical Oncology. 35(15_suppl). 3027–3027. 14 indexed citations

16.

Melero, Ignacio, Neil H. Segal, Willeke Ros, et al.. (2017). Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2549–2549. 1 indexed citations

17.

Tabernero, Josep, Ignacio Melero, Willeke Ros, et al.. (2017). Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). 3002–3002. 128 indexed citations

18.

Diab, Adi, Anthony B. El-Khoueiry, Ferry A.L.M. Eskens, et al.. (2016). A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies. Annals of Oncology. 27. vi361–vi361. 12 indexed citations

19.

Brummelen, Emilie M.J. van, Willeke Ros, Gertjan Wolbink, Jos H. Beijnen, & Jan H.M. Schellens. (2016). Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. The Oncologist. 21(10). 1260–1268. 100 indexed citations

20.

Hamid, Omid, John A. Thompson, Adi Diab, et al.. (2016). First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.. Journal of Clinical Oncology. 34(15_suppl). 3079–3079. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact